News headlines about AVEO Pharmaceuticals (NASDAQ:AVEO) have trended somewhat positive on Tuesday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5238138300756 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern’s scoring:

A number of equities analysts have recently issued reports on AVEO shares. ValuEngine lowered shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies restated a “positive” rating on shares of AVEO Pharmaceuticals in a research report on Friday, June 23rd. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Monday, July 24th. Finally, FBR & Co restated an “outperform” rating and set a $3.00 target price on shares of AVEO Pharmaceuticals in a research report on Thursday, July 13th.

AVEO Pharmaceuticals (NASDAQ AVEO) opened at 2.67 on Tuesday. The stock’s market capitalization is $294.67 million. The stock’s 50 day moving average is $2.06 and its 200-day moving average is $1.04. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.19.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact AVEO Pharmaceuticals (NASDAQ:AVEO) Share Price” was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.